3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
27
Phase 3
24
Phase 2
24
Phase 1/2
18
Phase EARLY_PHASE1
2
Phase 4
2
Phase NA
1
Phase 2/3
1
Status
Recruiting
1
Not yet recruiting
1
Sponsor Class
INDUSTRY
2
OTHER
1
Study Type
Interventional
2
Sponsor
Cancer Type
Myeloid
2
Other hematologic neoplasm
1
Conditions
Neoplasms
66
Breast Neoplasms
64
Prostatic Neoplasms
46
Carcinoma, Non-Small-Cell Lung
40
Neoplasm Metastasis
23
Colorectal Neoplasms
21
Multiple Myeloma
20
Pain
19
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
16
Anemia
16
Keratosis, Actinic
15
Lung Neoplasms
14
Cancer Pain
14
Lymphoma, Non-Hodgkin
12
Lymphoma, Follicular
11
Leukemia
11
Leukemia, Lymphocytic, Chronic, B-Cell
10
Carcinoma, Renal Cell
10
Carcinoma, Hepatocellular
9
Carcinoma
9
Neuroendocrine Tumors
8
Melanoma
8
Lymphoma
8
Ovarian Neoplasms
7
Leukemia, Myeloid, Acute
7
Uterine Cervical Neoplasms
6
Recurrence
6
Gastrointestinal Stromal Tumors
6
Stomatitis
5
Stomach Neoplasms
5
Interventions
nilotinib
1
bosutinib
1
asciminib
1
Phlebotomy
1
Imatinib Mesylate
1
Dasatinib
1
Aspirin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 4
×
INDUSTRY
×
Myeloproliferative Disorders
×
Clear all
NCT04877522
2026-05-11
Asciminib Roll-over Study
Novartis
Phase 4
Recruiting
347 enrolled
NCT06290765
2025-07-31
PV
PharmaEssentia
Phase 4
Not yet recruiting
70 enrolled